Rheumatology 2002; 41: 484-489
© 2002 British Society for Rheumatology
Original Papers |
Anti-tumour necrosis factor (TNF)-
therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis
Department of Rheumatology, Karolinska Hospital and
1 Department of Rheumatology, Huddinge Hospital, Stockholm, Sweden
Objectives. Matrix metalloproteinases (MMPs) are cytokine-modulated enzymes that play an important role in the pathogenesis of rheumatoid arthritis (RA) by inducing bone resorption and cartilage destruction. This study evaluated the modulation of serum and synovial MMPs and their inhibitor, tissue inhibitor of matrix metalloproteinases (TIMP)-1, by therapy with soluble tumour necrosis factor (TNF) 
receptor (etanercept).
Methods. Serum samples were collected from 60 RA patients at baseline and after 8 or 12 weeks of treatment. Paired synovial biopsies were obtained from 11 patients at two time points, before and after 8 weeks of treatment. We measured serum levels of MMP-1, MMP-3 and TIMP-1 by ELISA. Immunohistological analysis of synovial tissue was performed using monoclonal antibodies specific for MMP-1, MMP-3 and TIMP-1.
Results. Etanercept therapy significantly down-regulated serum levels of MMP-3 and MMP-1 in parallel with the reduction in inflammatory parameters (C-reactive protein concentration and erythrocyte sedimentation rate) in RA patients. Baseline pretreatment serum levels of MMP-3 correlated with changes in clinical disease activity during therapy. No consistent changes in serum level of TIMP-1 were observed, while ratios of MMP-1 and MMP-3 to TIMP-1 were down-regulated following etanercept treatment. Immunohistochemical analyses revealed great interindividual variability, with generally a high level of expression of MMP and low expression of TIMP. No significant change in the pattern or number of positive cells occurred during therapy.
Conclusions. In RA patients, etanercept therapy down-regulates serum levels of MMP-3 and MMP-1 and the ratio between MMPs and TIMP-1. This may be an important mechanism for the prevention of future development of joint damage.
KEY WORDS: Rheumatoid arthritis, Soluble tumour necrosis factor receptor, Etanercept, Metalloproteinases, Tissue inhibitors of metalloproteinases.
Correspondence to: A. I. Catrina, Rheumatology Research Laboratory, CMM L8-004, Karolinska Hospital, S-17176, Stockholm, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F Chopin, P Garnero, A le Henanff, F Debiais, A Daragon, C Roux, J Sany, D Wendling, C Zarnitsky, P Ravaud, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis Ann Rheum Dis, March 1, 2008; 67(3): 353 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Koca, A. Isik, I. H. Ozercan, B. Ustundag, B. Evren, and K. Metin Effectiveness of etanercept in bleomycin-induced experimental scleroderma Rheumatology, February 1, 2008; 47(2): 172 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Gottlieb, F. Chamian, S. Masud, I. Cardinale, M. V. Abello, M. A. Lowes, F. Chen, M. Magliocco, and J. G. Krueger TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques J. Immunol., August 15, 2005; 175(4): 2721 - 2729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Kruithof, D Baeten, F Van den Bosch, H Mielants, E M Veys, and F De Keyser Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy Ann Rheum Dis, April 1, 2005; 64(4): 529 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Drewe, M. L. Huggins, A. G. Morgan, M. J. D. Cassidy, and R. J. Powell Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome Rheumatology, November 1, 2004; 43(11): 1405 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Rowan, W. Hui, T. E. Cawston, and C. D. Richards Adenoviral Gene Transfer of Interleukin-1 in Combination with Oncostatin M Induces Significant Joint Damage in a Murine Model Am. J. Pathol., June 1, 2003; 162(6): 1975 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A I Catrina, A K Ulfgren, S Lindblad, L Grondal, and L Klareskog Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium Ann Rheum Dis, October 1, 2002; 61(10): 934 - 936. [Abstract] [Full Text] [PDF]
|
|